Activation Of The Mapk Pathway Mediates Resistance To Pi3k Inhibitors In Chronic Lymphocytic Leukemia
BLOOD(2021)
Abstract
Inhibitors of Bruton tyrosine kinase (BTK) and phosphatidylinositol 3-kinase delta (PI3K delta) that target the B-cell receptor (BCR) signaling pathway have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Mutations associated with resistance to BTK inhibitors have been identified, but limited data are available on mechanisms of resistance to PI3K delta inhibitors. Here we present findings from longitudinal whole-exome sequencing of cells from patients with multiply relapsed CLL (N = 28) enrolled in trials of PI3K inhibitors. The nonresponder subgroup was characterized by baseline activating mutations in MAP2K1, BRAF, and KRAS genes in 60% of patients. PI3K delta inhibition failed to inhibit ERK phosphorylation (pERK) in nonresponder CLL cells with and without mutations, whereas treatment with a MEK inhibitor rescued ERK inhibition. Overexpression of MAP2K1 mutants in vitro led to increased basal and inducible pERK and resistance to idelalisib. These data demonstrate that MAPK/ERK activation plays a key role in resistance to PI3K delta inhibitors in CLL and provide a rationale for therapy with a combination of PI3K delta and ERK inhibitors.
MoreTranslated text
Key words
mapk pathway,chronic lymphocytic leukemia,pi3k,inhibitors
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined